Results 101 to 110 of about 11,081 (214)
Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application
MedComm, Volume 7, Issue 6, June 2026.The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang +12 more
wiley +1 more source
Кардиоваскулярная терапия и профилактика, 2005 Aim. To assess effects of orlistat and its combimation with enalapril on main cardiovascular risk parameters in young patients with obesity and arterial hypertension. Material and methods.
A. G. Avtandilov +3 more
doaj
Orlistat targets NEDD8 conjugating enzyme UBC12 for cancer therapy
Pharmacological ResearchColorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and one of the best-characterized drivers is oncogenic Wnt signaling.
Mengzhen Shen +11 more
doaj +1 more source
Obesity, Volume 34, Issue 6, Page 1237-1242, June 2026.ABSTRACT Objective This study aimed to describe parental communication with children around obesity management medications (OMMs) and child, parent, and family factors associated with communication. Methods Parents (N = 211; 80% mothers; 89% White) prescribed OMMs at a medical center participated in a survey about communication with children about OMM ...
Keeley J. Pratt +3 more
wiley +1 more source
Obesity, Volume 34, Issue 6, Page 1343-1353, June 2026.ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez +10 more
wiley +1 more source
Effect of Orlistat in Obese Patients with Binge Eating Disorder
, 2005 OBJECTIVE: Binge eating disorder represents a significant public health problem, with up to 50% of weight loss program participants displaying this disorder. In previous studies with orlistat, patients with binge eating disorder were excluded.
Frank Habicht +13 more
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4795-4805, June 2026.ABSTRACT Aims To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida.
Hamlet Gasoyan +9 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna +10 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue S3, Page 3-15, June 2026.ABSTRACT The duodenum has historically been regarded as a passive digestive conduit for nutrient transit and absorption. However, emerging experimental and clinical evidence supports a revision of this view. In a contemporary model, the proximal small intestine also has roles as a metabolic sensor and endocrine signalling hub that exerts a powerful ...
David A. D’Alessio +1 more
wiley +1 more source
Evaluation of gut microbiota alterations following orlistat administration in obese mice
Frontiers in EndocrinologyBackgroundThe gut microbiota plays a pivotal role in various metabolic disorders. Orlistat has shown beneficial effects on weight loss and metabolism, but its direct impact on the gut microbiota has not been extensively reported.
Chang Xue +5 more
doaj +1 more source